BR112022020232A2 - Anticorpos contra nkp46 e construtos dos mesmos para o tratamento de cânceres e infecções - Google Patents

Anticorpos contra nkp46 e construtos dos mesmos para o tratamento de cânceres e infecções

Info

Publication number
BR112022020232A2
BR112022020232A2 BR112022020232A BR112022020232A BR112022020232A2 BR 112022020232 A2 BR112022020232 A2 BR 112022020232A2 BR 112022020232 A BR112022020232 A BR 112022020232A BR 112022020232 A BR112022020232 A BR 112022020232A BR 112022020232 A2 BR112022020232 A2 BR 112022020232A2
Authority
BR
Brazil
Prior art keywords
infections
treatment
nkp46
constructs
cancer
Prior art date
Application number
BR112022020232A
Other languages
English (en)
Inventor
Jonjic Stipan
Mandelboim Ofer
Berhani Orit
Kahalon Shira
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Univ Of Rijeka Faculty Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd, Univ Of Rijeka Faculty Of Medicine filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of BR112022020232A2 publication Critical patent/BR112022020232A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPOS CONTRA NKp46 E CONSTRUTOS DOS MESMOS PARA O TRATAMENTO DE CÂNCERES E INFECÇÕES. A presente invenção provê anticorpos monoclonais que reconhecem NKp46 humano com alta afinidade e especificidade e não bloqueiam a ligação de NKp46 aos seus ligantes naturais. A presente invenção provê adicionalmente anticorpos multiespecíficos, receptores de antígenos quiméricos (CAR) e usos dos mesmos no tratamento de doenças, particularmente malignidades e infecções.
BR112022020232A 2020-04-06 2021-04-05 Anticorpos contra nkp46 e construtos dos mesmos para o tratamento de cânceres e infecções BR112022020232A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063005457P 2020-04-06 2020-04-06
PCT/IL2021/050381 WO2021205438A1 (en) 2020-04-06 2021-04-05 Antibodies to nkp46 and constructs thereof for treatment of cancers and infections

Publications (1)

Publication Number Publication Date
BR112022020232A2 true BR112022020232A2 (pt) 2022-12-13

Family

ID=75746987

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020232A BR112022020232A2 (pt) 2020-04-06 2021-04-05 Anticorpos contra nkp46 e construtos dos mesmos para o tratamento de cânceres e infecções

Country Status (9)

Country Link
US (1) US20230183342A1 (pt)
EP (1) EP4132568A1 (pt)
JP (1) JP2023520587A (pt)
KR (1) KR20220164787A (pt)
CN (1) CN115768467A (pt)
AU (1) AU2021253899A1 (pt)
BR (1) BR112022020232A2 (pt)
CA (1) CA3179348A1 (pt)
WO (1) WO2021205438A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022200525A1 (en) * 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
MX2023014647A (es) * 2021-06-09 2024-01-31 Innate Pharma Proteinas de union a nkp46 multiespecificas.
CN116003595B (zh) * 2022-07-11 2024-02-02 南方医科大学第三附属医院（广东省骨科研究院） 靶向nk细胞nkp46受体的纳米抗体及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
DK0654085T3 (da) 1992-01-23 1997-09-22 Merck Patent Gmbh Monomere og dimere antistof-fragment-fusionsproteiner
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0827544B1 (en) 1995-05-23 2004-08-18 MorphoSys AG Multimeric proteins
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
JP5978314B2 (ja) 2011-12-27 2016-08-24 エルジー・ケム・リミテッド リチウム二次電池及びその製造方法
EP3161002A1 (en) * 2014-06-27 2017-05-03 Innate Pharma MULTISPECIFIC NKp46 BINDING PROTEINS
CA3007898A1 (en) * 2015-12-28 2017-07-06 Innate Pharma Variable regions for nkp46 binding proteins
WO2018047154A1 (en) * 2016-09-07 2018-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-nkp46 antibodies and therapeutic use of same

Also Published As

Publication number Publication date
CN115768467A (zh) 2023-03-07
US20230183342A1 (en) 2023-06-15
WO2021205438A1 (en) 2021-10-14
EP4132568A1 (en) 2023-02-15
CA3179348A1 (en) 2021-10-14
AU2021253899A1 (en) 2022-11-17
JP2023520587A (ja) 2023-05-17
KR20220164787A (ko) 2022-12-13

Similar Documents

Publication Publication Date Title
BR112022020232A2 (pt) Anticorpos contra nkp46 e construtos dos mesmos para o tratamento de cânceres e infecções
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
ZA201901591B (en) Anti¿muc16 (mucin 16) antibodies
CL2020003179A1 (es) (divisional de solicitud 713-2015) anticuerpos anti-cd3, moleculas de union a antígeno biespecificas que se unen a cd3 y cd20; y usos de los mismos.
Mussai et al. Cytotoxicity of the anti‐CD22 immunotoxin HA22 (CAT‐8015) against paediatric acute lymphoblastic leukaemia
MY195059A (en) Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
MX2019005911A (es) Anticuerpos anti_cd137 novedosos y usos de estos.
EA201890368A1 (ru) Антитела против псма, биспецифичные антигенсвязывающие молекулы, которые связывают псма и cd3, и их применение
PH12021551238A1 (en) Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
MX2021000392A (es) Anticuerpos anti-mesotelina.
NZ737726A (en) Multispecific antigen-binding molecules and uses thereof
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
MX2020007401A (es) Novedosa combinacion y uso de anticuerpos.
ZA202008095B (en) Humanized antibodies against psma
BR112022019758A2 (pt) Agente imunoteranóstico alvejando células cancerígenas derivadas de células-tronco mesenquimais e doença associada a células-tronco mesenquimais
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
MX2021015270A (es) Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb.
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
BR112022012872A2 (pt) Composição e uso de anticorpos monoclonais geneticamente modificados refratários a fatores imunossupressivos tumorais
EA201990784A1 (ru) Анти-muc16 (mucin16) антитела
MX2022002371A (es) Un anticuerpo de dominio único para dirigirse al antígeno de membrana específico de la próstata (psma).
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.
PH12020500172A1 (en) Antibody specifically binding to pauf and use thereof